Displaying 61 - 80 of 496
FTC Order Requires Pyrex Glass Manufacturer to Pay for Falsely Claiming Chinese Products Were Made in USA
Dissenting Statement of Commissioner Christine S. Wilson Regarding the Matter of Prudential Security
Statement of Chair Lina M. Khan, Joined by Commissioners Slaughter and Bedoya, in the matters of Prudential Security, O-I Glass, Inc., and Ardagh Group, S.A.
FTC Seeks Public Comment on Potential Updates to its ‘Green Guides’ for the Use of Environmental Marketing Claims
16 CFR Part 260: Guides for the Use of Environmental Marketing Claims (Green Guides)
Statement of Commissioner Rebecca Kelly Slaughter Joined by Chair Lina M. Khan
FTC Approves Final Order against Electrowarmth Products, LLC and its Owner, Barring Them from Deceptive Made in USA Labeling Claims
Agency Information Collection Activities; Proposed Collection; Comment Request; Extension (Warranty Rule)
FTC Approves Final Orders in Right-to-Repair Cases Against Harley-Davidson, MWE Investments, and Weber
FTC Sues Heated Mattress Pads Marketer Electrowarmth for Falsely Claiming that Chinese Products Were Made in the USA
FTC Sues Marketer of Personal Protective Equipment and Light Fixtures for Advertising Claims About Products Being Made in the USA and Government-Certified
Federal Trade Commission Finalizes Action Against “Made in USA” Offender Who Ripped “Made in China” Tags Out of Apparel, Replacing Them with “Made in USA” Tags
FTC Approves Final Order Preserving Competition for Development and Marketing of Steroid Injectable Drug
Hikma Pharmaceuticals/Custopharm
As a condition of Hikma Pharmaceuticals PLC’s $375 million acquisition of generic drug services company Custopharm, Inc., the Federal Trade Commission required Custopharm’s parent company, private equity fund Water Street Healthcare Partners, LLC to retain and transfer Custopharm’s assets related to the corticosteroid drug triamcinolone acetonide, or TCA, to another company Water Street owns, Long Grove Pharmaceuticals, LLC. According to the complaint, absent a remedy, Hikma likely would have stopped developing its injectable TCA product, forestalling the increased price competition it would have brought to the market. Thus without this remedy, the acquisition likely would have harmed future competition in the U.S. market for injectable triamcinolone acetonide.
FTC Takes Action Against Weber for Illegally Restricting Customers’ Right to Repair
FTC Seeks Public Comment on Amplifier Rule Amendments to Make Testing Methods More Useful to Consumers
Displaying 61 - 80 of 496